DaxibotulinumtoxinA

Generic Name
DaxibotulinumtoxinA
Brand Names
Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
E211KPY694
Background

DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
...

Indication

DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.

Associated Conditions
Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
Associated Therapies
-
Clinical Trials
Related News

Botulinum Toxin Injection for Functional Popliteal Artery Entrapment Syndrome

First Posted Date
2018-08-15
Last Posted Date
2021-03-08
Lead Sponsor
Stanford University
Registration Number
NCT03631966
Locations
🇺🇸

Stanford University, Redwood City, California, United States

Treatment of Hypertrophic Scars With Intradermal Botox

Phase 2
Conditions
Hypertrophic Scar
Interventions
Drug: Botox
First Posted Date
2018-08-15
Last Posted Date
2018-09-26
Lead Sponsor
Roy G. Geronemus, M.D.
Target Recruit Count
20
Registration Number
NCT03631368
Locations
🇺🇸

Laser & Skin Surgery Center of New York, New York, New York, United States

Pharmacodynamic and Safety of MBA-P01 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: MBA-P01
Drug: BOTOX
First Posted Date
2018-06-06
Last Posted Date
2019-03-26
Lead Sponsor
Medy-Tox
Target Recruit Count
28
Registration Number
NCT03547141
Locations
🇰🇷

The Catholic University of Korea, St. Paul's Hospital, Seoul, Korea, Republic of

BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

Conditions
Dysphonia
Interventions
Drug: BOTOX
First Posted Date
2018-06-01
Last Posted Date
2021-10-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
400
Registration Number
NCT03543150
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

Assessment of Gait After Dysport Treatment

Phase 4
Completed
Conditions
Equinovarus; Acquired
Interventions
Drug: Dysport
First Posted Date
2018-04-18
Last Posted Date
2020-03-02
Lead Sponsor
Albert Einstein Healthcare Network
Target Recruit Count
11
Registration Number
NCT03501043
Locations
🇺🇸

MossRehab, Elkins Park, Pennsylvania, United States

Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder

Phase 1
Completed
Conditions
Overactive Bladder
Interventions
Drug: Meditoxin
Drug: Botox
First Posted Date
2017-12-13
Last Posted Date
2019-03-27
Lead Sponsor
Medy-Tox
Target Recruit Count
30
Registration Number
NCT03371342
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination

Phase 4
Terminated
Conditions
Stroke
Muscle Spasticity
Interventions
Drug: Botox
First Posted Date
2017-12-08
Last Posted Date
2021-12-29
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
4
Registration Number
NCT03367429
Locations
🇺🇸

NewYork Presbyterian Hospital - Weill Cornell Medicine, New York, New York, United States

Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Meditoxin
Drug: Botox
First Posted Date
2017-10-23
Last Posted Date
2019-03-27
Lead Sponsor
Medy-Tox
Target Recruit Count
25
Registration Number
NCT03317717
Locations
🇰🇷

The Catholic University of Korea, St. Paul's Hospital, Seoul, Korea, Republic of

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

Phase 3
Completed
Conditions
Essential Blepharospasm
Interventions
Drug: Neuronox
Drug: Botox
First Posted Date
2017-07-13
Last Posted Date
2017-07-13
Lead Sponsor
Medy-Tox
Target Recruit Count
140
Registration Number
NCT03216473

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

Phase 3
Completed
Conditions
Glabellar Lines
Interventions
Drug: Neuronox
Drug: Botox
First Posted Date
2017-07-13
Last Posted Date
2017-07-13
Lead Sponsor
Medy-Tox
Target Recruit Count
504
Registration Number
NCT03216408
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy